Suppr超能文献

美国老年 HER2 阳性转移性乳腺癌女性的指南一致治疗。

Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.

机构信息

Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island.

出版信息

J Natl Compr Canc Netw. 2020 Apr;18(4):405-413. doi: 10.6004/jnccn.2019.7373.

Abstract

BACKGROUND

It is crucial to identify whether women with HER2-positive (HER2+) metastatic breast cancer (MBC) are treated according to treatment guidelines and whether treatment disparities exist. This study examined guideline-concordant treatment among women with HER2+ MBC and determined the magnitude of differences in treatment between those with positive and negative hormone receptor (HR) status using a nonlinear decomposition technique.

METHODS

A retrospective observational cohort study was conducted using the SEER-Medicare linked database. The study cohort consisted of women aged ≥66 years diagnosed with HER2+ MBC in 2010 through 2013 (n=241). Guideline-concordant initial treatment after cancer diagnosis was defined based on the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. A multivariable logistic regression was performed to identify significant predictors of guideline-concordant treatment. A postregression decomposition was conducted to identify the magnitude of disparities in treatment by HR status.

RESULTS

Of 241 women included in the study, a total of 76.8% received guideline-concordant treatment. These women were significantly more likely to have positive HR status (P=.0298), have good performance status (P=.0009), and more oncology visits (P<.0001). With 1-year increments in age at cancer diagnosis, the likelihood of receiving guideline-concordant treatment reduced by 5% (P=.0356). The decomposition analysis revealed that 19.0% of the disparity in guideline-concordant treatment between women with positive and negative HR status was explained by differences in their characteristics. Enabling characteristics (marital status, income, and education) explained the highest (22.8%) proportion of the disparity.

CONCLUSIONS

Nearly one-quarter of the study cohort did not receive guideline-concordant treatment. Our findings suggest opportunities to improve cancer care for elderly women with negative HR status who are unpartnered or have lower socioeconomic status. The high unexplained portion of the disparity by HR status can be due to patient treatment preferences, propensity to seek care, and organizational and physician-level characteristics that were not included in the study.

摘要

背景

确定患有 HER2 阳性(HER2+)转移性乳腺癌(MBC)的女性是否按照治疗指南进行治疗以及是否存在治疗差异至关重要。本研究通过非线性分解技术检查了 HER2+MBC 女性的指南一致治疗,并确定了激素受体(HR)状态阳性和阴性患者之间治疗差异的幅度。

方法

使用 SEER-Medicare 链接数据库进行回顾性观察队列研究。研究队列包括 2010 年至 2013 年诊断为 HER2+MBC 的年龄≥66 岁的女性(n=241)。癌症诊断后根据 NCCN 临床肿瘤学乳腺癌实践指南定义初始治疗的指南一致性。进行多变量逻辑回归以确定指南一致治疗的显著预测因素。进行回归后分解以确定 HR 状态下治疗差异的幅度。

结果

在纳入的 241 名女性中,共有 76.8%接受了指南一致的治疗。这些女性更有可能具有阳性 HR 状态(P=.0298)、良好的表现状态(P=.0009)和更多的肿瘤学就诊次数(P<.0001)。癌症诊断时年龄每增加 1 岁,接受指南一致治疗的可能性降低 5%(P=.0356)。分解分析显示,HR 状态阳性和阴性女性之间在指南一致治疗方面的差异中有 19.0%可以用其特征差异来解释。使能特征(婚姻状况、收入和教育)解释了差异的最高(22.8%)比例。

结论

近四分之一的研究队列未接受指南一致的治疗。我们的研究结果表明,有机会改善无伴侣或社会经济地位较低的 HR 状态阴性老年女性的癌症护理。HR 状态差异的未解释部分很高,这可能是由于患者的治疗偏好、寻求护理的倾向以及研究中未包括的组织和医生层面的特征所致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验